Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics

Fig. 1

FGF-23 in patients receiving treatment with GLP-1 analogues alone or in combination with other anti-diabetes medication compared to those who did not receive treatment with GLP-1 analogues (a). FGF-23 in patients with and without peripheral neuropathy (b). Correlation between FGF-23 and myocardial perfusion reserve (MPR) (c) and FGF-23 and E/e* as a measure of cardiac diastolic function (d)

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840